Immunohistochemical Detection of the Cyclin-dependent Kinase Inhibitor 2/Multiple Tumor Suppressor Gene 1 (CDKN2/MTS1) Product p16INK4A in Archival Human Solid Tumors: Correlation with Retinoblastoma Protein Expression

Cancer Research

Volumn 55, Issue 24, 1995, Pages 6006-6011

  Geradts, Joseph ^a   Kratzke, Robert A ^b   Niehans, Gloria A ^b   Lincoln, Clint E ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GENE PRODUCT; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; SOLID TUMOR;

CARRIER PROTEINS; CELL NUCLEUS; CYTOPLASM; HUMAN; IMMUNOENZYME TECHNIQUES; NEOPLASMS; PROTEIN P16; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED;

EID: 0028865984     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Goodrich, D. W., Wang, N. P., Qian, Y. W., Lee, E. Y. H. P., and Lee, W. H. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell, 67: 293-302, 1991.
2. Xu, H. J., Hu, S. X., and Benedict, W. F. Lack of nuclear RB protein staining in Go/middle G1 cells: correlation to changes in total Rb protein level. Oncogene, 6: 1139-1146, 1991.
3. Kamb, A. Cell-cycle regulators and cancer. Trends Genet., 11: 136-140, 1995.
4. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
5. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. Retinoblastoma protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375: 503-506, 1995.
6. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Lie, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
7. Mori, T., Miura, K., Aoki, T., Nishihira, T., Mori, S., and Nakamura, Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54: 3396-3397, 1994.
8. Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W., and Kaye, F. J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene, 9: 3375-3378, 1994.
9. Liu, Q., Neuhausen, S., McClure, M., Frye, C., Weaver-Feldhaus, J., Gruis, N. A., Eddington, K., Allalunis-Turner, M. J., Skolnick, M. H., Fujimura, F. K., and Kamb, A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 10: 1061-1067, 1995.
10. Spruck, C. H., Gonzalez-Zulueta, M., Shibata, A., Simoneau, A. R., Lin, M. F., Gonzales, F., Tsai, Y. C., and Jones, P. A. p16 gene in uncultured tumours. Nature (Lond.), 370: 183-184, 1994.
11. Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., Beach, D. H., and Harris, C. C. Mutations and altered expression of pl6INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045-11049, 1994.
12. Merlo, A., Herman, J. G., Mao, L., Lee, D., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor pl6/CDKN2/MTSl in human cancers. Nat. Med., 1: 686-692, 1995.
13. Quesnel, B., Fenaux, P., Philippe, N., Fournier, J., Bonneterre, J., Preudhomme, C., and Peyrat, J. P. Analysis of pl6 gene deletion and point mutation in breast carcinoma. Oncogene, 10: 351-353, 1995.
14. Jin, J., Harper, W., Bigner, S. H., Bigner, D. D., Papadopoulos, N., Markowitz, S., Willson, J. K. V., Kinzler, K. W., and Vogelstein, B. Deletion of pl6 and p15 genes in brain tumors. Cancer Res., 54: 6353-6358, 1994.
15. Otterson, G. A., Khleif, S. N., Chen, W., Coxon, A. B., and Kaye, F. J. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of pl6 protein induction by 5-aza 2′deoxycytidine. Oncogene, 11: 1211-1216, 1995.
16. Zhou, X., Tarmin, L., Jing, Y., Hiang, H. Y., Suzuki, H., Rhyu, M. G., Abraham, J. M., and Meltzer, S. J. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene, 9: 3737-3741, 1994.
17. Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J., Richards, W., Sugarbaker, D. J., and Rollins, B. J. Reciprocal Rb inactivation and pl6INK4 expression in primary lung cancers and cell lines. Cancer Res., 55: 505-509, 1995.
18. Xu, L., Sgroi, D., Sterner, C. J., Beauchamp, R. L., Pinney, D. M., Keel, S., Ueki, K., Rutter, J. L., Buckler, A. J., Louis, D. N., Gusella, J. F., and Ramesh, V. Mutational analysis of CDKN2 (MTSl/pl6INK4) in human breast carcinomas. Cancer Res., 54: 5262-5264, 1994.
19. Shimizu, E., Coxon, A., Otterson, G., Steinberg, S. M., Kratzke, R. A., Kim, Y. W., Fedorko, J., Oie, H., Johnson, B. E., Mulshine, J. L., Minna, J. D., Gazdar, A. F., and Kaye, F. J. Rb protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene, 9: 2441-2448, 1994.
20. Kratzke, R. A., Shimizu, E., Geradts, J., Gerster, J. L., Segal, S., Otterson, G. A., and Kaye, F. J. RB-mediated tumor suppression of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix. Cell Growth & Differ., 4: 629-635, 1993.
21. Wen, S. F., Nodelman, M., Nared-Hood, K., Duncan, J., Geradts, J., and Shepard, H. M. Retinoblastoma protein monoclonal antibodies with novel characteristics. J. Immunol. Methods, 169: 231-240, 1994.
22. Kratzke, R. A., Otterson, G. A., Lin, A. Y., Shimizu, E., Alexandrova, N., Zajac-Kaye, M., Horowitz, J. M., and Kaye, F. J. Functional analysis of the Cys706 residue of the retinoblastoma protein. J. Biol. Chem., 267: 25998-26003, 1992.
23. Geradts, J., Hu, S. X., Lincoln, C. E., Benedict, W. F., and Xu, H. J. Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies. Int. J. Cancer, 58: 161-167, 1994.
24. Geradts, J., Kratzke, R. A., Crush-Stanton, S., Wen, S. F., and Lincoln, C. E. Immunocytochemical detection of wild type and mutant retinoblastoma protein in paraffin sections: differential sensitivities and specificities of anti-RB monoclonal antibodies. Mod. Pathol., in press, 1996.
25. Serrano, M., Gomez-Lahoz, E., DePinho, R. A., Beach, D., and Bar-Sagi, D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science (Washington DC), 767: 249-252, 1995.
26. Tam, S. W., Shay, J. W., and Pagano, M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor pl6INK4. Cancer Res., 54: 5816-5820, 1994.
27. Reed, J. A., Loganzo, F., Shea, C. R., Walker, G. J., Flores, J. F., Glendenberg, J. M., Bogdany, J. K., Shiel, M. J., Haluska, F. G., Fountain, J. W., and Albino, A. P. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res., 55: 2713-2718, 1995.
28. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor pl6 by the retinoblastoma susceptibility gene product pRb. Cancer Res., 54: 6078-6082, 1994.